Athersys (NASDAQ:ATHX) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX) in a note issued to investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Performance

Shares of ATHX opened at $0.03 on Friday. The firm has a market capitalization of $731,250.00, a P/E ratio of -0.01 and a beta of -0.59. The stock’s fifty day simple moving average is $0.26 and its 200 day simple moving average is $0.61. Athersys has a twelve month low of $0.02 and a twelve month high of $2.54.

Athersys (NASDAQ:ATHX) last issued its earnings results on Wednesday, August 16th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter. The company had revenue of $0.05 million during the quarter.

Institutional Trading of Athersys

Several large investors have recently added to or reduced their stakes in the stock. State Street Corp increased its holdings in Athersys by 45.2% in the 1st quarter. State Street Corp now owns 42,413 shares of the biopharmaceutical company’s stock valued at $52,000 after purchasing an additional 13,200 shares in the last quarter. Vahanian & Associates Financial Planning Inc. increased its holdings in Athersys by 2.8% in the 2nd quarter. Vahanian & Associates Financial Planning Inc. now owns 841,430 shares of the biopharmaceutical company’s stock valued at $732,000 after purchasing an additional 23,080 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Athersys by 5.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 575,537 shares of the biopharmaceutical company’s stock valued at $349,000 after purchasing an additional 30,249 shares in the last quarter. Simplicity Solutions LLC acquired a new stake in Athersys in the 1st quarter valued at $39,000. Finally, CIBC Asset Management Inc acquired a new stake in Athersys in the 1st quarter valued at $45,000. 19.35% of the stock is currently owned by institutional investors and hedge funds.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.